PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27022719-8 2016 The tissue oxidative parameters such as lipid peroxidation, glutathione, catalase and superoxide dismutase was significantly changed as the results of free DOX treatment. Doxorubicin 156-159 catalase Mus musculus 73-81 31125824-6 2019 DOX increased the mRNA expression levels of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and the antioxidant genes heme-oxygenase-1 (HO-1) and catalase (CAT), while reducing the levels of glutathione peroxidase (GSH-Px) and superoxide dismutase-1 (SOD-1) compared with those of the control. Doxorubicin 0-3 catalase Mus musculus 149-157 31125824-6 2019 DOX increased the mRNA expression levels of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and the antioxidant genes heme-oxygenase-1 (HO-1) and catalase (CAT), while reducing the levels of glutathione peroxidase (GSH-Px) and superoxide dismutase-1 (SOD-1) compared with those of the control. Doxorubicin 0-3 catalase Mus musculus 159-162 31141523-9 2019 Superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) levels were significantly increased, whereas the level of lipid peroxidation was significantly decreased in HCC mice treated with DOX, PCA-ZnAl and ZnAl-LDH compared with those in HCC mice treated with saline. Doxorubicin 196-199 catalase Mus musculus 28-36 31141523-9 2019 Superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH) levels were significantly increased, whereas the level of lipid peroxidation was significantly decreased in HCC mice treated with DOX, PCA-ZnAl and ZnAl-LDH compared with those in HCC mice treated with saline. Doxorubicin 196-199 catalase Mus musculus 38-41 25053391-8 2014 Meloxicam normalized doxorubicin-induced suppression in heart antioxidant enzymes activities and gene expressions [superoxide dismutase, glutathione peroxidase (GSH-Px) and catalase], and heart GSH content. Doxorubicin 21-32 catalase Mus musculus 173-181 26603425-10 2016 DOX or I3C alone or in combination induced significant increase in tumor CAT and SOD with significant decrease in tumor volume, tumor MDA, SphK1 activity and IL-6 and alleviated the histopathological changes with significant increase in the apoptotic index and significant decrease in tissue bcl2 compared to SEC group. Doxorubicin 0-3 catalase Mus musculus 73-76 24228387-3 2013 Administration of lycopene (LycT) extracted from tomato to DOX treated mice showed a significant reduction in serum creatinine and urea levels which were associated with significantly low levels of LPO and significantly enhanced level of GSH and related antioxidant enzymes activity (GPx, GR and CAT) when compared to DOX group. Doxorubicin 59-62 catalase Mus musculus 296-299 24799355-5 2014 Doxorubicin disturbed kidney histology, abrogated renal function tests (serum creatinine, uric acid, and blood urea nitrogen), induced a significant decrease in antioxidant enzyme activities (superoxide dismutase, glutathione peroxidase, and catalase) and reduced glutathione (GSH) content. Doxorubicin 0-11 catalase Mus musculus 242-250 24479327-6 2013 It has been shown that the administration of a carrier containing doxorubicin to mice with Lewis lung carcinoma caused the decrease of catalase activity in mice with carcinoma. Doxorubicin 66-77 catalase Mus musculus 135-143 9788901-3 1998 Transgenic mice overexpressing three isoforms of superoxide dismutase, catalase, and the cellular glutathione peroxidase (GSHPx-1) in various tissues show an increased tolerance to ischemia-reperfusion heart and brain injury, hyperoxia, cold-induced brain edema, adriamycin, and paraquat toxicity. Doxorubicin 263-273 catalase Mus musculus 71-79 24175309-6 2013 Statistical significant increased MDA levels and SOD and CAT enzymes activities were found in the liver homogenates of tumor bearing mice after alone treatment with DOX or gamma-irradiation compared to the control mice, while these parameters were insignificantly increased after BLM administration compared to the same controls. Doxorubicin 165-168 catalase Mus musculus 57-60 21463615-7 2011 These toxic responses were stronger in the hearts of MT(-/-) mice that were more vulnerable to doxorubicin-induced oxidative injury as exhibited by increased lipid peroxidation and decreased catalase and glutathione peroxidase (GSH-Px) expression. Doxorubicin 95-106 catalase Mus musculus 191-199 11800590-0 2002 Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts. Doxorubicin 14-25 catalase Mus musculus 46-54 11800590-1 2002 Catalase is an important antioxidant enzyme, which has been shown to provide cardiac protection from acute toxicity induced by doxorubicin, a most effective anticancer agent. Doxorubicin 127-138 catalase Mus musculus 0-8 11800590-2 2002 Because cumulative dose-dependent chronic cardiomyopathy due to a long-term administration of doxorubicin is a significant clinical problem, the present study was undertaken to test the hypothesis that catalase also provides protection against doxorubicin chronic cardiotoxicity. Doxorubicin 94-105 catalase Mus musculus 202-210 11800590-2 2002 Because cumulative dose-dependent chronic cardiomyopathy due to a long-term administration of doxorubicin is a significant clinical problem, the present study was undertaken to test the hypothesis that catalase also provides protection against doxorubicin chronic cardiotoxicity. Doxorubicin 244-255 catalase Mus musculus 202-210 11800590-3 2002 Transgenic mice containing cardiac catalase activities of 15-, 60-, or 100-fold higher than normal and nontransgenic controls were treated with doxorubicin in a cumulative dose of 45 mg/kg in five equal iv injections (9 mg/kg every other week) over a period of 10 weeks. Doxorubicin 144-155 catalase Mus musculus 35-43 11800590-9 2002 The results indicate that catalase elevation in the heart prevents doxorubicin chronic cardiomyopathy. Doxorubicin 67-78 catalase Mus musculus 26-34 21556506-0 1995 Induction of p-glycoprotein, glutathione-s-transferase-pi, catalase, C-fos and C-erbb1 in rodent cell-lines after exposure to Doxorubicin, ethanol and caffeine. Doxorubicin 126-137 catalase Mus musculus 59-67 9604692-0 1997 The in vitro study on genotoxic activity of adriamycin and bleomycin in cells of mice with different catalase and superoxide dismutase activity. Doxorubicin 44-54 catalase Mus musculus 101-109 8647872-0 1996 Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. Doxorubicin 15-26 catalase Mus musculus 63-71 8647872-1 1996 Weak antioxidant capacity, particularly low catalase activity in the heart, may be a factor responsible for the high sensitivity of this organ to doxorubicin-induced oxidative damage. Doxorubicin 146-157 catalase Mus musculus 44-52 8647872-8 1996 As compared to normal controls, transgenic lines expressing catalase activity 60- or 100-fold higher than normal exhibited a significant resistance to doxorubicin-induced cardiac lipid peroxidation, elevation of serum creatine phosphokinase, and functional changes in the isolated atrium. Doxorubicin 151-162 catalase Mus musculus 60-68 8647872-10 1996 The results provide direct evidence for the role of catalase in doxorubicin cardiotoxic responses. Doxorubicin 64-75 catalase Mus musculus 52-60 21556506-2 1995 P-glycoprotein (P-170), glutathione S-transferase-pi (GST-pi) and catalase (CAT) levels were found to be elevated after exposure of the cells to doxorubicin. Doxorubicin 145-156 catalase Mus musculus 66-74 21556506-2 1995 P-glycoprotein (P-170), glutathione S-transferase-pi (GST-pi) and catalase (CAT) levels were found to be elevated after exposure of the cells to doxorubicin. Doxorubicin 145-156 catalase Mus musculus 76-79 2496064-0 1989 Effect of adriamycin on the activities of superoxide dismutase, glutathione peroxidase and catalase in tissues of mice. Doxorubicin 10-20 catalase Mus musculus 91-99 2115781-1 1990 Our data suggest that DOX resistance in P388/R-84 cells may result, at least in part, from reduced free radical formation by both suppression of flavin reductase(s) and overexpression of certain antioxidant enzymes such as GSH peroxidase and catalase. Doxorubicin 22-25 catalase Mus musculus 242-250 34234834-9 2021 KXS reduced neural degeneration and protected against DOX-induced oxidative stress according to decreased malondialdehyde level, increased glutathione level, and enhanced activities of superoxide dismutase, catalase, and glutathione peroxidase. Doxorubicin 54-57 catalase Mus musculus 207-215 34760256-8 2021 Further mechanism studies showed that pretreatment with NMCP-2 counteracted the oxidative stress induced by DOX, as indicated by increasing superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) activities, and malondialdehyde (MDA) production decreased. Doxorubicin 108-111 catalase Mus musculus 168-176 34760256-8 2021 Further mechanism studies showed that pretreatment with NMCP-2 counteracted the oxidative stress induced by DOX, as indicated by increasing superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) activities, and malondialdehyde (MDA) production decreased. Doxorubicin 108-111 catalase Mus musculus 178-181 34328254-13 2021 Moreover, DOX significantly reduced the levels of total antioxidant capacity and activities of catalase and glutathione S-transferase. Doxorubicin 10-13 catalase Mus musculus 95-103 2496064-1 1989 The increment of lipid peroxide in the hearts of mice treated with adriamycin (ADR) was examined in relation to the decrease in the activities of superoxide dismutase (SOD), glutathione peroxidase (GSHpx) and catalase. Doxorubicin 67-77 catalase Mus musculus 209-217 3163942-10 1988 Catalase specific activity increased by 119.9% in the doxorubicin animals, by 73% in the epirubicin mice and by 30.3% in the mitoxantrone ones. Doxorubicin 54-65 catalase Mus musculus 0-8 3428124-0 1987 Effects of doxorubicin on mouse heart catalase. Doxorubicin 11-22 catalase Mus musculus 38-46 3428124-5 1987 Analyses by gel filtration excluded the possibility that doxorubicin induces major changes in the molecular properties of heart catalase. Doxorubicin 57-68 catalase Mus musculus 128-136 3428124-6 1987 In vivo experiments with aminotriazole, which blocks catalase irreversibly, indicated that doxorubicin stimulates the synthesis of cardiac catalase. Doxorubicin 91-102 catalase Mus musculus 53-61 3428124-6 1987 In vivo experiments with aminotriazole, which blocks catalase irreversibly, indicated that doxorubicin stimulates the synthesis of cardiac catalase. Doxorubicin 91-102 catalase Mus musculus 139-147 3428124-8 1987 The catalase elevation could represent a reaction by the heart to free radicals generated by doxorubicin. Doxorubicin 93-104 catalase Mus musculus 4-12 6324993-8 1984 Measured catalase activity in drug-resistant P388 cells was one-third of the activity measured in doxorubicin-sensitive P388 cells. Doxorubicin 98-109 catalase Mus musculus 9-17 6306200-2 1983 The activities of superoxide dismutase and catalase in the heart of mice were increased significantly by the intraperitoneal administration of 15 mg/kg of adriamycin. Doxorubicin 155-165 catalase Mus musculus 43-51 32673667-6 2020 The DOX group showed increased 8-hydroxy-2"-deoxyguanosine (8-OHdG) levels in the heart, whereas the DOX + STS group showed increased catalase and superoxide dismutase (SOD) activities and decreased 8-OHdG levels in the heart compared with DOX group, suggesting that STS reduces DOX-induced DNA damage by improving antioxidant enzymes activities in cardiomyocytes. Doxorubicin 101-104 catalase Mus musculus 134-142 32673667-6 2020 The DOX group showed increased 8-hydroxy-2"-deoxyguanosine (8-OHdG) levels in the heart, whereas the DOX + STS group showed increased catalase and superoxide dismutase (SOD) activities and decreased 8-OHdG levels in the heart compared with DOX group, suggesting that STS reduces DOX-induced DNA damage by improving antioxidant enzymes activities in cardiomyocytes. Doxorubicin 101-104 catalase Mus musculus 134-142 32673667-6 2020 The DOX group showed increased 8-hydroxy-2"-deoxyguanosine (8-OHdG) levels in the heart, whereas the DOX + STS group showed increased catalase and superoxide dismutase (SOD) activities and decreased 8-OHdG levels in the heart compared with DOX group, suggesting that STS reduces DOX-induced DNA damage by improving antioxidant enzymes activities in cardiomyocytes. Doxorubicin 101-104 catalase Mus musculus 134-142 32854544-5 2022 Treatment of DLA mice with DOX alone resulted in reduced GSH contents, and decreased the activities of glutathione-s-transferase (GST), catalase (CAT), and superoxide dismutase (SOD). Doxorubicin 27-30 catalase Mus musculus 136-144 32854544-5 2022 Treatment of DLA mice with DOX alone resulted in reduced GSH contents, and decreased the activities of glutathione-s-transferase (GST), catalase (CAT), and superoxide dismutase (SOD). Doxorubicin 27-30 catalase Mus musculus 146-149 32854544-6 2022 Treatment of DOX-administered DLA mice with G. applanatum however increased the GSH content and elevated the activities of GST, CAT, and SOD. Doxorubicin 13-16 catalase Mus musculus 128-131